恩曲替尼治疗NTRK1融合基因阳性肝内胆管癌后的认知和共济失调不良事件：一例报告
Cognitive and ataxic adverse events following entrectinib treatment in NTRK1 fusion gene-positive intrahepatic cholangiocarcinoma: a case report.
作者信息
Koyama Kazuya, Iwamoto Hidetaka, Takahashi Kenji, Okada Tetsuhiro, Kawabata Hidemasa, Kitano Yohei, Tanabe Hiroki, Fujiya Mikihiro, Okumura Toshikatsu, Mizukami Yusuke
机构信息
Division of Gastroenterology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka Higashi, Asahikawa, Hokkaido, 078-8510, Japan.
Genetic Oncology Department, Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan.
出版信息
Clin J Gastroenterol. 2025 Feb;18(1):183-187. doi: 10.1007/s12328-024-02076-w. Epub 2024 Dec 7.
We report the rare case of severe cognitive disorder and ataxia caused by entrectinib in a patient with NTRK1 fusion gene-positive intrahepatic cholangiocarcinoma. The case was a 56-year-old woman after nine courses of GCS therapy. The patient experienced grade 1 muscle weakness on day 4 and grade 3, cognitive disorder on day 7 after receiving entrectinib, which led to hospitalization. The symptoms were reversible and tended to improve after withdrawal of entrectinib. It is crucial to increase awareness of TRKi-specific adverse events and their proper management.
我们报告了1例由恩曲替尼引起的严重认知障碍和共济失调的罕见病例，该患者为NTRK1融合基因阳性的肝内胆管癌患者。该病例为一名56岁女性，接受了9个疗程的GCS治疗。患者在接受恩曲替尼治疗后第4天出现1级肌肉无力，第7天出现3级认知障碍，随后住院治疗。这些症状是可逆的，在停用恩曲替尼后病情趋于改善。提高对TRKi特异性不良事件及其合理管理的认识至关重要。
Zotero 插件